PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company that is focused on finding novel therapies for cardiovascular and cardiopulmonary diseases. Its pipeline includes bentracimab, a reversal agent for ticagrelor, PB1046 for pulmonary arterial hypertension and hospitalized COVID-19 patients and PB6440 for resistant hypertension. The company utilizes its proprietary elastin-like polypeptide technology platform to develop therapies with better pharmacokinetics and less-frequent dosing, which leads to both internal and partnership drug-development opportunities.
PhaseBio Pharmaceuticals, Inc.'s ticker is PHAS
The company's shares trade on the NASDAQ stock exchange
They are based in Malvern, Pennsylvania
There are 11-50 employees working at PhaseBio Pharmaceuticals, Inc.
It is https://phasebio.com/
PhaseBio Pharmaceuticals, Inc. is in the Healthcare sector
PhaseBio Pharmaceuticals, Inc. is in the Biotechnology industry
The following five companies are PhaseBio Pharmaceuticals, Inc.'s industry peers:
- Cellular Biomedicine Group Inc